Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaiyesimi, I. A.
Right arrow Articles by Hortobagyi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaiyesimi, I. A.
Right arrow Articles by Hortobagyi, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 10, 1014-1024, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Inflammatory breast cancer: a review

IA Jaiyesimi, AU Buzdar and G Hortobagyi
Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030.

PURPOSE: The natural history of inflammatory breast cancer and the recent advances in its management were reviewed. DESIGN: The English medical literature from 1924 to 1990 was reviewed using the Cancerline and Medline retrieval systems, and through a manual review of bibliographies of identified articles. RESULTS: The majority of patients with inflammatory breast cancer treated only with local therapies died 18 to 24 months after diagnosis. A combined modality approach with chemotherapy, surgery, and radiation therapy has improved disease-free and overall survival rates for inflammatory breast cancer. Approximately 35% to 55% of patients treated with combined modality regimens remain disease-free and alive at 5 years. CONCLUSION: Induction combination chemotherapy administered with radiation therapy, mastectomy, both, or with additional chemotherapy favorably alters the natural history of inflammatory breast cancer. New drug combinations and high-dose chemotherapy with autologous bone marrow support are being evaluated to improve further patient survival.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
S. Carkaci, H. A. Macapinlac, M. Cristofanilli, O. Mawlawi, E. Rohren, A. M. Gonzalez Angulo, S. Dawood, E. Resetkova, H. T. Le-Petross, and W.-T. Yang
Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data
J. Nucl. Med., February 1, 2009; 50(2): 231 - 238.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, S.-W. Kau, R. Islam, G. N. Hortobagyi, and M. Cristofanilli
Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer
Clin. Cancer Res., March 15, 2008; 14(6): 1718 - 1725.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. M. Gonzalez-Angulo, B. T. Hennessy, K. Broglio, F. Meric-Bernstam, M. Cristofanilli, S. H. Giordano, T. A. Buchholz, A. Sahin, S. E. Singletary, A. U. Buzdar, et al.
Trends for Inflammatory Breast Cancer: Is Survival Improving?
Oncologist, August 1, 2007; 12(8): 904 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. M. Nguyen, K. Sam, A. Tsimelzon, X. Li, H. Wong, S. Mohsin, G. M. Clark, S. G. Hilsenbeck, R. M. Elledge, D. C. Allred, et al.
Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype
Clin. Cancer Res., September 1, 2006; 12(17): 5047 - 5054.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
R. L. Smoot, C. A. Koch, A. C. Degnim, S. Sterioff, J. H. Donohue, C. S. Grant, S. A. Barnes, R. E. Gullerud, T. J. Hobday, and D. R. Farley
A Single-Center Experience With Inflammatory Breast Cancer, 1985-2003
Arch Surg, June 1, 2006; 141(6): 567 - 573.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Panades, I. A. Olivotto, C. H. Speers, T. Shenkier, T. A. Olivotto, L. Weir, S. J. Allan, and P. T. Truong
Evolving Treatment Strategies for Inflammatory Breast Cancer: A Population-Based Survival Analysis
J. Clin. Oncol., March 20, 2005; 23(9): 1941 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Bertucci, P. Finetti, J. Rougemont, E. Charafe-Jauffret, N. Cervera, C. Tarpin, C. Nguyen, L. Xerri, R. Houlgatte, J. Jacquemier, et al.
Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast Cancer
Cancer Res., March 15, 2005; 65(6): 2170 - 2178.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Bertucci, P. Finetti, J. Rougemont, E. Charafe-Jauffret, V. Nasser, B. Loriod, J. Camerlo, R. Tagett, C. Tarpin, G. Houvenaeghel, et al.
Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy
Cancer Res., December 1, 2004; 64(23): 8558 - 8565.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Bieche, F. Lerebours, S. Tozlu, M. Espie, M. Marty, and R. Lidereau
Molecular Profiling of Inflammatory Breast Cancer: Identification of a Poor-Prognosis Gene Expression Signature
Clin. Cancer Res., October 15, 2004; 10(20): 6789 - 6795.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Gonzalez-Angulo, N. Sneige, A. U. Buzdar, V. Valero, S.-W. Kau, K. Broglio, Y. Yamamura, G. N. Hortobagyi, and M. Cristofanilli
p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer
Clin. Cancer Res., September 15, 2004; 10(18): 6215 - 6221.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. H. Giordano
Update on Locally Advanced Breast Cancer
Oncologist, December 1, 2003; 8(6): 521 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Lerebours, P. Bertheau, I. Bieche, L.-F. Plassa, M.-H. Champeme, K. Hacene, C. Toulas, M. Espie, M. Marty, and R. Lidereau
Two Prognostic Groups of Inflammatory Breast Cancer Have Distinct Genotypes
Clin. Cancer Res., September 15, 2003; 9(11): 4184 - 4189.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Cristofanilli, A. U. Buzdar, and G. N. Hortobagyi
Update on the Management of Inflammatory Breast Cancer
Oncologist, April 1, 2003; 8(2): 141 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. J. McCarthy, X. Yang, I. R. Linnoila, M. J. Merino, S. M. Hewitt, A. L. Parr, S. Paik, S. M. Steinberg, D. P. Hartmann, N. Mourali, et al.
Microvessel Density, Expression of Estrogen Receptor {alpha}, MIB-1, p53, and c-erbB-2 in Inflammatory Breast Cancer
Clin. Cancer Res., December 1, 2002; 8(12): 3857 - 3862.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias, M. De Carvalho, E. A. Mesri, D. M. Robins, R. D. Dick, et al.
Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis
Cancer Res., September 1, 2002; 62(17): 4854 - 4859.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. L. van Golen, L. Bao, M. M. DiVito, Z. Wu, G. C. Prendergast, and S. D. Merajver
Reversion of RhoC GTPase-induced Inflammatory Breast Cancer Phenotype by Treatment with a Farnesyl Transferase Inhibitor
Mol. Cancer Ther., June 1, 2002; 1(8): 575 - 583.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
I. Gunhan-Bilgen, E. E. Ustun, and A. Memis
Inflammatory Breast Carcinoma: Mammographic, Ultrasonographic, Clinical, and Pathologic Findings in 142 Cases
Radiology, June 1, 2002; 223(3): 829 - 838.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. El-Tamer, S. Hussain, J. Weedon, H. Chalchal, A. Chakrabarti, C. Sohn, and A. S. Braverman
Prognoses of T4 Breast Cancer Subsets
Ann. Surg. Oncol., May 1, 2002; 9(4): 340 - 345.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H.M. Pinedo, T.D. de Gruijl, E. van der Wall, and J. Buter
Biological Concepts of Prolonged Neoadjuvant Treatment plus GM-CSF in Locally Advanced Tumors
Oncologist, December 1, 2000; 5(6): 497 - 500.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
K. L. van Golen, Z.-F. Wu, X. T. Qiao, L. W. Bao, and S. D. Merajver
RhoC GTPase, a Novel Transforming Oncogene for Human Mammary Epithelial Cells That Partially Recapitulates the Inflammatory Breast Cancer Phenotype
Cancer Res., October 1, 2000; 60(20): 5832 - 5838.
[Abstract] [Full Text]

Home page
 JCOHome page
G. Macquart-Moulin, P. Viens, T. Palangie, M.-L. Bouscary, T. Delozier, H. Roche, M. Janvier, M. Fabbro, and J.-P. Moatti
High-Dose Sequential Chemotherapy With Recombinant Granulocyte Colony-Stimulating Factor and Repeated Stem-Cell Support for Inflammatory Breast Cancer Patients: Does Impact on Quality of Life Jeopardize Feasibility and Acceptability of Treatment?
J. Clin. Oncol., February 14, 2000; 18(4): 754 - 754.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Nieto, P. J. Cagnoni, E. J. Shpall, X. Xu, J. Murphy, J. Vredenburgh, N. J. Chao, S. I. Bearman, and R. B. Jones
A Predictive Model for Relapse in High-Risk Primary Breast Cancer Patients Treated with High-Dose Chemotherapy and Autologous Stem-Cell Transplant
Clin. Cancer Res., November 1, 1999; 5(11): 3425 - 3431.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. L. van Golen, S. Davies, Z. Fen Wu, Y. Wang, C. D. Bucana, H. Root, S. Chandrasekharappa, M. Strawderman, S. P. Ethier, and S. D. Merajver
A Novel Putative Low-Affinity Insulin-like Growth Factor-binding Protein, LIBC (Lost in Inflammatory Breast Cancer), and RhoC GTPase Correlate with the Inflammatory Breast Cancer Phenotype
Clin. Cancer Res., September 1, 1999; 5(9): 2511 - 2519.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Adkins, R. Brown, K. Trinkaus, R. Maziarz, S. Luedke, C. Freytes, B. Needles, D. Wienski, P. Fracasso, T. Pluard, et al.
Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer
J. Clin. Oncol., July 1, 1999; 17(7): 2006 - 2006.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. H. Honkoop, S. A. Luykx-de Bakker, K. Hoekman, S. Meyer, O. W.M. Meyer, C. J. van Groeningen, P. J. van Diest, E. Boven, E. van der Wall, G. Giaccone, et al.
Prolonged Neoadjuvant Chemotherapy with GM-CSF in Locally Advanced Breast Cancer
Oncologist, April 1, 1999; 4(2): 106 - 111.
[Abstract] [Full Text]

Home page
 NEJMHome page
G. N. Hortobagyi
Treatment of Breast Cancer
N. Engl. J. Med., October 1, 1998; 339(14): 974 - 984.
[Full Text] [PDF]

Home page
 The OncologistHome page
V. Valero, A. U. Buzdar, and G. N. Hortobagyi
Locally Advanced Breast Cancer
Oncologist, February 1, 1996; 1(1): 8 - 17.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1992 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online